IHF:NYE-iShares U.S. Healthcare Providers ETF (USD)

ETF | Health |

Last Closing

USD 53.01

Change

-0.02 (-0.04)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.41 (+0.96%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+0.84 (+1.20%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+0.80 (+0.73%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.02 (+1.07%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.78 (+3.48%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.67 (+2.03%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.37 (+0.36%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.59 (+1.93%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.21 (+1.95%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.79 (+3.41%)

USD 6.89M

ETFs Containing IHF

MSSS Northern Lights Fund Trus.. 9.86 % 0.00 %

+0.23 (+0.80%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.46% 90% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.46% 90% A- 89% A-
Trailing 12 Months  
Capital Gain 0.36% 14% F 33% F
Dividend Return 0.78% 56% F 9% A-
Total Return 1.14% 14% F 23% F
Trailing 5 Years  
Capital Gain 31.62% 57% F 64% D
Dividend Return 5.17% 63% D 14% F
Total Return 36.80% 52% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 5.33% 62% D 52% F
Dividend Return 5.97% 62% D 46% F
Total Return 0.64% 63% D 16% F
Risk Return Profile  
Volatility (Standard Deviation) 21.65% 43% F 50% F
Risk Adjusted Return 27.57% 57% F 42% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.